Ellenberg A H, Braun H
Plast Reconstr Surg. 1980 Mar;65(3):307-13. doi: 10.1097/00006534-198003000-00006.
The use of the double-lumen implant, with 20 mg of Solu-Medrol or less, has improved the final results in patients having reconstruction after mastectomy. However, the results in patients having augmentation mammaplasties have been much more dramatic, with far superior results over those patients having a gel implant. During the first year the incidence of scar tissue problems is 17 times greater with the gel implants than with the double-lumen implants and 20 mg or less of Solu-Medrol. Scar capsules were also extremely amenable to closed capsulotomy after augmentation with the double-lumen implant, in marked contrast to the gel implant. There is no evidence to support the hypothesis that the double-lumen implant and Solu-Medrol merely delays the eventual appearance of the scar tissue problem. The recommended dosage of Solu-Medrol would appear to be 20 mg and not less.
使用含20毫克或更少甲强龙的双腔植入物，改善了乳房切除术后进行重建患者的最终效果。然而，在隆胸患者中，效果更为显著，比使用凝胶植入物的患者效果要好得多。在第一年，凝胶植入物出现瘢痕组织问题的发生率比双腔植入物及20毫克或更少甲强龙的情况高17倍。与凝胶植入物形成鲜明对比的是，双腔植入物隆胸后，瘢痕包膜对闭合性包膜切开术也极为敏感。没有证据支持双腔植入物和甲强龙只是延迟瘢痕组织问题最终出现这一假设。甲强龙的推荐剂量似乎为20毫克且不能更少。
